In the clinical setting, it has been reported that serum levels of E-selectin are significantly higher in patients with advanced breast cancer that have distant metastasis compared to earlier stage patients [42,43,44], and that high E-selectin serum concentrations are prognostic of a worse outcome [44,45]. The gene discussed is SELE; the disease is breast carcinoma.